Cancer comes in many forms, but the abnormal cells tend to travel through the body via the bloodstream.
It’s only when the cancer cells form a mass that traditional diagnostic imaging techniques can identify the problem and shape a counterattack.
What if a new technology could identify cancer five to 12 months earlier? And what if this new technology could also offer clues on the most effective countermeasures?
That’s the vision of Triantafyllos (Fyl) Tafas, founder, CEO and director at QCDx (Quantitative Cell Diagnostix) in Farmington.